WO1998015637A1 - Herpes simplex virus strains - Google Patents
Herpes simplex virus strains Download PDFInfo
- Publication number
- WO1998015637A1 WO1998015637A1 PCT/US1997/008681 US9708681W WO9815637A1 WO 1998015637 A1 WO1998015637 A1 WO 1998015637A1 US 9708681 W US9708681 W US 9708681W WO 9815637 A1 WO9815637 A1 WO 9815637A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hsv
- icp4
- gene
- icp27
- cells
- Prior art date
Links
- 241000700584 Simplexvirus Species 0.000 title description 146
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 157
- 101710130522 mRNA export factor Proteins 0.000 claims abstract description 85
- 230000035772 mutation Effects 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 24
- 101150027427 ICP4 gene Proteins 0.000 claims abstract description 16
- 108700002232 Immediate-Early Genes Proteins 0.000 claims abstract description 13
- 230000003111 delayed effect Effects 0.000 claims abstract description 11
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 6
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 6
- 239000002157 polynucleotide Substances 0.000 claims abstract description 6
- 241000700605 Viruses Species 0.000 claims description 74
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 claims description 37
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 claims description 37
- 238000012217 deletion Methods 0.000 claims description 23
- 230000037430 deletion Effects 0.000 claims description 23
- 108020004414 DNA Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 101150044021 UL41 gene Proteins 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 16
- 108091026890 Coding region Proteins 0.000 claims description 14
- 230000002068 genetic effect Effects 0.000 claims description 13
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 claims description 10
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 6
- 230000000415 inactivating effect Effects 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 102000000311 Cytosine Deaminase Human genes 0.000 claims description 2
- 108010080611 Cytosine Deaminase Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims 1
- 229960004927 neomycin Drugs 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 46
- 101150090364 ICP0 gene Proteins 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 222
- 208000015181 infectious disease Diseases 0.000 description 46
- 230000014509 gene expression Effects 0.000 description 41
- 210000003501 vero cell Anatomy 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 230000003612 virological effect Effects 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 108010005774 beta-Galactosidase Proteins 0.000 description 16
- 230000012010 growth Effects 0.000 description 15
- 230000001413 cellular effect Effects 0.000 description 14
- 230000002950 deficient Effects 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 102000004243 Tubulin Human genes 0.000 description 12
- 108090000704 Tubulin Proteins 0.000 description 12
- 208000036815 beta tubulin Diseases 0.000 description 12
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 12
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 11
- 238000001243 protein synthesis Methods 0.000 description 11
- 230000014616 translation Effects 0.000 description 11
- 101150102264 IE gene Proteins 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 230000006648 viral gene expression Effects 0.000 description 8
- 101100427508 Human cytomegalovirus (strain AD169) UL39 gene Proteins 0.000 description 7
- 101150093191 RIR1 gene Proteins 0.000 description 7
- 238000002105 Southern blotting Methods 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 230000004543 DNA replication Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000001902 propagating effect Effects 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- -1 ICPO Proteins 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 108091092356 cellular DNA Proteins 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000004451 qualitative analysis Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 108010007403 Immediate-Early Proteins Proteins 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 101710186352 Probable membrane antigen 3 Proteins 0.000 description 1
- 101710181078 Probable membrane antigen 75 Proteins 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710178472 Tegument protein Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003415 peat Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000004537 potential cytotoxicity Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 230000007419 viral reactivation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
- C12N2710/16652—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/194,274 US6261552B1 (en) | 1997-05-22 | 1997-05-22 | Herpes simplex virus vectors |
JP51203698A JP2001503611A (en) | 1996-05-22 | 1997-05-22 | Herpes simplex virus strain |
CA002255939A CA2255939A1 (en) | 1996-05-22 | 1997-05-22 | Herpes simplex virus strains |
DE69738709T DE69738709D1 (en) | 1996-05-22 | 1997-05-22 | HERPES SIMPLEX VIRUS STAEMME |
EP97926668A EP0904395B2 (en) | 1996-05-22 | 1997-05-22 | Herpes simplex virus strains |
AU31379/97A AU733945B2 (en) | 1996-05-22 | 1997-05-22 | Herpes simplex virus strains |
US10/427,739 US7078029B2 (en) | 1996-05-22 | 2003-05-01 | Herpes simplex virus strains |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/651,419 US5804413A (en) | 1992-07-31 | 1996-05-22 | Herpes simplex virus strains for gene transfer |
US08/651,419 | 1996-05-22 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/651,419 Continuation-In-Part US5804413A (en) | 1992-07-31 | 1996-05-22 | Herpes simplex virus strains for gene transfer |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/194,274 A-371-Of-International US6261552B1 (en) | 1996-05-22 | 1997-05-22 | Herpes simplex virus vectors |
US09194274 A-371-Of-International | 1997-05-22 | ||
US09/829,839 Continuation US20010026799A1 (en) | 1996-05-22 | 2001-04-10 | Herpes simplex virus strains |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998015637A1 true WO1998015637A1 (en) | 1998-04-16 |
Family
ID=24612790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/008681 WO1998015637A1 (en) | 1996-05-22 | 1997-05-22 | Herpes simplex virus strains |
Country Status (8)
Country | Link |
---|---|
US (1) | US5804413A (en) |
EP (1) | EP0904395B2 (en) |
JP (1) | JP2001503611A (en) |
AT (1) | ATE396274T1 (en) |
AU (1) | AU733945B2 (en) |
CA (1) | CA2255939A1 (en) |
DE (1) | DE69738709D1 (en) |
WO (1) | WO1998015637A1 (en) |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001009361A1 (en) * | 1999-08-03 | 2001-02-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Recombinant hsv-1 and live viral vaccines |
US6248320B1 (en) | 1996-07-26 | 2001-06-19 | University College London | HSV strain lacking functional ICP27 and ICP34.5 genes |
WO2001053507A1 (en) * | 2000-01-21 | 2001-07-26 | Biovex Limited | Replication competent herpes virus strains |
WO2002056828A3 (en) * | 2000-11-29 | 2002-10-03 | Univ Rochester | Helper virus-free herpes virus amplicon particles and uses thereof |
US7262033B1 (en) * | 1998-08-03 | 2007-08-28 | Biovex Limited | Cell lines for the propagation of mutated herpes viruses |
US7531167B2 (en) | 2004-10-28 | 2009-05-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Herpes simplex virus vector |
US7825231B2 (en) | 2005-06-01 | 2010-11-02 | Darren P. Wolfe | Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy |
WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
US8092791B2 (en) | 2001-05-23 | 2012-01-10 | University Of Rochester | Method of producing herpes simplex virus amplicons, resulting amplicons, and their use |
WO2012122025A2 (en) | 2011-03-04 | 2012-09-13 | Intrexon Corporation | Vectors conditionally expressing protein |
EP2824185A1 (en) | 2003-02-24 | 2015-01-14 | GenVec, Inc. | Materials and methods for treating disorders of the ear |
WO2015009952A1 (en) * | 2013-07-17 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
US8957036B2 (en) | 2007-05-14 | 2015-02-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Targeted delivery of glycine receptors to excitable cells |
WO2016037164A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
WO2017132552A1 (en) | 2016-01-27 | 2017-08-03 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
WO2017165813A1 (en) | 2016-03-25 | 2017-09-28 | Periphagen, Inc. | High-transducing hsv vectors |
EP3284821A1 (en) | 2010-03-23 | 2018-02-21 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
WO2018035141A1 (en) | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
WO2018039333A1 (en) | 2016-08-23 | 2018-03-01 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
WO2018049226A1 (en) | 2016-09-08 | 2018-03-15 | Bluebird Bio, Inc. | Pd-1 homing endonuclease variants, compositions, and methods of use |
US9951351B2 (en) | 2014-10-09 | 2018-04-24 | Genvec, Inc. | Adenoviral vector encoding human atonal homolog-1 (HATH1) |
WO2018094244A1 (en) | 2016-11-17 | 2018-05-24 | Bluebird Bio, Inc. | TGFβ SIGNAL CONVERTOR |
WO2018129268A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
WO2018152325A1 (en) | 2017-02-15 | 2018-08-23 | Bluebird Bio, Inc. | Donor repair templates multiplex genome editing |
WO2018176103A1 (en) | 2017-03-30 | 2018-10-04 | The University Of Queensland | "chimeric molecules and uses thereof" |
WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2019165436A1 (en) | 2018-02-26 | 2019-08-29 | Antolrx | Tolerogenic liposomes and methods of use thereof |
WO2019241685A1 (en) | 2018-06-14 | 2019-12-19 | Bluebird Bio, Inc. | Cd79a chimeric antigen receptors |
WO2020185298A1 (en) * | 2019-03-14 | 2020-09-17 | Massachusetts Institute Of Technology | Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof |
US10793843B2 (en) | 2018-10-04 | 2020-10-06 | Bluebird Bio, Inc. | CBLB endonuclease variants, compositions, and methods of use |
US10799560B2 (en) | 2016-03-25 | 2020-10-13 | Periphagen, Inc. | HSV vectors for delivery of NT3 and treatment of CIPN |
WO2020223205A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
WO2020243261A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
US10927367B2 (en) | 2017-05-25 | 2021-02-23 | Bluebird Bio, Inc. | CBLB endonuclease variants, compositions, and methods of use |
WO2021072310A1 (en) | 2019-10-10 | 2021-04-15 | Oncorus, Inc. | Dual viruses and dual oncolytic viruses and methods of treatment |
WO2021207636A2 (en) | 2020-04-10 | 2021-10-14 | Sola Biosciences Llc | Compositions and methods for the treatment of protein aggregation disorders |
WO2021222168A2 (en) | 2020-04-28 | 2021-11-04 | Sola Biosciences Llc | Compositions and methods for the treatment of tdp-43 proteinopathies |
WO2021248038A1 (en) | 2020-06-05 | 2021-12-09 | Sola Biosciences Llc | Compositions and methods for the treatment of synucleinopathies |
WO2021252549A1 (en) | 2020-06-09 | 2021-12-16 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
WO2022093736A1 (en) | 2020-10-26 | 2022-05-05 | Sola Biosciences Llc | Compositions and methods for the treatment of alzheimer's disease |
US11530395B2 (en) | 2016-10-17 | 2022-12-20 | 2Seventy Bio, Inc. | TGFBetaR2 endonuclease variants, compositions, and methods of use |
WO2023288267A1 (en) | 2021-07-14 | 2023-01-19 | 2Seventy Bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
WO2023060221A2 (en) | 2021-10-08 | 2023-04-13 | Sola Biosciences Llc | Compositions and methods for the treatment of proteopathies |
WO2023060248A1 (en) | 2021-10-08 | 2023-04-13 | Sola Biosciences Llc | Compositions and methods for the treatment of p53-mediated cancers |
WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
US11779654B2 (en) | 2017-10-04 | 2023-10-10 | 2Seventy Bio, Inc. | PCSK9 endonuclease variants, compositions, and methods of use |
WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7223411B1 (en) * | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
GB9415369D0 (en) | 1994-07-29 | 1994-09-21 | Lynxvale Ltd | Mutant virus |
US6261552B1 (en) * | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
US6764675B1 (en) * | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
CA2374745A1 (en) * | 1999-08-09 | 2001-02-15 | Incyte Genomics, Inc. | Proteases and protease inhibitors |
EP1210429A2 (en) * | 1999-09-10 | 2002-06-05 | Incyte Genomics, Inc. | Apoptosis proteins |
CA2382998A1 (en) * | 1999-12-08 | 2001-06-14 | Onyx Pharmaceuticals, Inc. | Mutant simplex virus for treating unwanted hyperproliferative cell growth |
EP1259611A2 (en) * | 2000-03-03 | 2002-11-27 | Incyte Genomics, Inc. | G-protein coupled receptors |
WO2001098323A2 (en) | 2000-06-16 | 2001-12-27 | Incyte Genomics, Inc. | G-protein coupled receptors |
US7608704B2 (en) | 2000-11-08 | 2009-10-27 | Incyte Corporation | Secreted proteins |
WO2003006658A1 (en) * | 2001-07-13 | 2003-01-23 | The General Hospital Corporation | Mutant herpes simplex virus that expresses yeast cytosine deaminase |
AU2003222225A1 (en) * | 2002-02-20 | 2003-09-09 | Incyte Corporation | Receptors and membrane-associated proteins |
DK1503788T3 (en) * | 2002-04-25 | 2011-10-17 | Shire Human Genetic Therapies | Treatment of alpha-galactosidase A deficiency |
AU2003265431A1 (en) * | 2002-08-13 | 2004-02-25 | Incyte Corporation | Cell adhesion and extracellular matrix proteins |
US20070219353A1 (en) * | 2002-09-03 | 2007-09-20 | Incyte Corporation | Immune Response Associated Proteins |
AU2003279829A1 (en) * | 2002-10-04 | 2004-05-04 | Incyte Corp | Protein modification and maintenance molecules |
US20050164275A1 (en) * | 2002-10-18 | 2005-07-28 | Incyte Corporation | Phosphodiesterases |
US20070009886A1 (en) * | 2002-11-12 | 2007-01-11 | Incyte Corporation | Carbohydrate-associated proteins |
WO2004044165A2 (en) * | 2002-11-13 | 2004-05-27 | Incyte Corporation | Lipid-associated proteins |
WO2004048550A2 (en) * | 2002-11-26 | 2004-06-10 | Incyte Corporation | Immune response associated proteins |
WO2004098539A2 (en) | 2003-04-30 | 2004-11-18 | Incyte Corporation | Kinases and phosphatases |
US20060275812A1 (en) * | 2005-06-01 | 2006-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Assay for agonists and antagonists of ion channels and for regulators of genetic expression |
WO2007016239A2 (en) * | 2005-07-29 | 2007-02-08 | President And Fellows Of Harvard College | Herpes simplex virus mutant and uses therefore |
EP1783210A1 (en) * | 2005-11-08 | 2007-05-09 | ProBioGen AG | Productivity augmenting protein factors, novel cell lines and uses thereof |
US8889622B2 (en) * | 2007-07-25 | 2014-11-18 | Washington University | Methods of inhibiting seizure in a subject |
US9593347B2 (en) | 2010-04-16 | 2017-03-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors |
SG11201603119RA (en) | 2013-10-28 | 2016-05-30 | Univ Pittsburgh | Oncolytic hsv vector |
US9580699B2 (en) | 2014-04-17 | 2017-02-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library |
ES2899978T3 (en) * | 2015-05-13 | 2022-03-15 | Sanofi Pasteur Inc | ICP0-mediated enhanced expression system |
RU2758007C2 (en) | 2016-06-30 | 2021-10-25 | Онкорус, Инк. | Delivery of therapeutic polypeptides via pseudotyped oncolytic viruses |
WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
EP3856761A1 (en) | 2018-09-24 | 2021-08-04 | Krystal Biotech, Inc. | Compositions and methods for the treatment of netherton syndrome |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0453242A1 (en) * | 1990-04-16 | 1991-10-23 | The General Hospital Corporation | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
WO1995013391A1 (en) * | 1993-11-10 | 1995-05-18 | University Of British Columbia | Method of treatment using, process of preparing, and composition comprising a recombinant hsv-1 |
WO1996024663A1 (en) * | 1995-02-09 | 1996-08-15 | Washington University | Herpes simplex virus mutants |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5026635A (en) * | 1987-05-19 | 1991-06-25 | Du Pont Merck Pharmaceutical | Stable human cell lines expressing an indicator gene product under virus-specific genetic controls |
US5674722A (en) * | 1987-12-11 | 1997-10-07 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
US5672344A (en) * | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
US5124263A (en) * | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
US5070010A (en) * | 1989-10-30 | 1991-12-03 | Hoffman-La Roche Inc. | Method for determining anti-viral transactivating activity |
-
1996
- 1996-05-22 US US08/651,419 patent/US5804413A/en not_active Expired - Lifetime
-
1997
- 1997-05-22 DE DE69738709T patent/DE69738709D1/en not_active Expired - Lifetime
- 1997-05-22 AT AT97926668T patent/ATE396274T1/en not_active IP Right Cessation
- 1997-05-22 EP EP97926668A patent/EP0904395B2/en not_active Expired - Lifetime
- 1997-05-22 WO PCT/US1997/008681 patent/WO1998015637A1/en active Application Filing
- 1997-05-22 JP JP51203698A patent/JP2001503611A/en active Pending
- 1997-05-22 CA CA002255939A patent/CA2255939A1/en not_active Abandoned
- 1997-05-22 AU AU31379/97A patent/AU733945B2/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0453242A1 (en) * | 1990-04-16 | 1991-10-23 | The General Hospital Corporation | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
WO1995013391A1 (en) * | 1993-11-10 | 1995-05-18 | University Of British Columbia | Method of treatment using, process of preparing, and composition comprising a recombinant hsv-1 |
WO1996024663A1 (en) * | 1995-02-09 | 1996-08-15 | Washington University | Herpes simplex virus mutants |
Non-Patent Citations (5)
Title |
---|
L. SAMANIEGO ET AL.: "Functional interactions between Herpes Simplex Virus Immediate-Early proteins during infection: Gene expression as a consequence of ICP27 and different domains of ICP4", JOURNAL OF VIROLOGY, vol. 69, no. 9, July 1995 (1995-07-01), AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 5705 - 5715, XP002056112 * |
L. SAMANIEGO ET AL.: "The Herpes Simplex Immediate-Early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of IPC4 and IPC27", JOURNAL OF VIROLOGY, vol. 71, no. 6, June 1997 (1997-06-01), AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 4614 - 4625, XP002056113 * |
N. WU ET AL.: "Prolonged expression and cell survival after infection by a Herpes Simplex Virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22", JOURNAL OF VIROLOGY, vol. 70, no. 9, July 1996 (1996-07-01), AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 6358 - 6369, XP002056111 * |
RIVERA-GONZALES ET AL., VIROLOGY, vol. 202, 1994, pages 550 - 564 |
See also references of EP0904395A1 |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248320B1 (en) | 1996-07-26 | 2001-06-19 | University College London | HSV strain lacking functional ICP27 and ICP34.5 genes |
US7262033B1 (en) * | 1998-08-03 | 2007-08-28 | Biovex Limited | Cell lines for the propagation of mutated herpes viruses |
WO2001009361A1 (en) * | 1999-08-03 | 2001-02-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Recombinant hsv-1 and live viral vaccines |
WO2001053507A1 (en) * | 2000-01-21 | 2001-07-26 | Biovex Limited | Replication competent herpes virus strains |
US8119118B2 (en) | 2000-11-29 | 2012-02-21 | University Of Rochester | Helper virus-free herpesvirus amplicon particles and uses thereof |
WO2002056828A3 (en) * | 2000-11-29 | 2002-10-03 | Univ Rochester | Helper virus-free herpes virus amplicon particles and uses thereof |
US8092791B2 (en) | 2001-05-23 | 2012-01-10 | University Of Rochester | Method of producing herpes simplex virus amplicons, resulting amplicons, and their use |
EP2824185A1 (en) | 2003-02-24 | 2015-01-14 | GenVec, Inc. | Materials and methods for treating disorders of the ear |
US7531167B2 (en) | 2004-10-28 | 2009-05-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Herpes simplex virus vector |
US8309349B2 (en) | 2004-10-28 | 2012-11-13 | University of Pittsburgh—of the Commonwealth System of Higher Education | Cell line |
EP2377882A1 (en) | 2004-10-28 | 2011-10-19 | University of Pittsburgh of the Commonwealth System of Higher Education | Peripherally delivered glutamatic acid decarboxylase gene therapy for spinal cord injury pain |
US7825231B2 (en) | 2005-06-01 | 2010-11-02 | Darren P. Wolfe | Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy |
US8003622B2 (en) | 2005-06-01 | 2011-08-23 | Darren Wolfe | Peptide biosynthesis and pain therapy |
US8846889B2 (en) | 2005-06-01 | 2014-09-30 | Darren P. Wolfe | Peptide biosynthesis and pain therapy |
US8957036B2 (en) | 2007-05-14 | 2015-02-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Targeted delivery of glycine receptors to excitable cells |
US10696727B2 (en) | 2007-05-14 | 2020-06-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Targeted delivery of glycine receptors to excitable cells |
US11725038B2 (en) | 2007-05-14 | 2023-08-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Targeted delivery of glycine receptors to excitable cells |
WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
EP3284821A1 (en) | 2010-03-23 | 2018-02-21 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
WO2012122025A2 (en) | 2011-03-04 | 2012-09-13 | Intrexon Corporation | Vectors conditionally expressing protein |
EP3450568A2 (en) | 2011-03-04 | 2019-03-06 | Intrexon Corporation | Vectors conditionally expressing protein |
WO2015009952A1 (en) * | 2013-07-17 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
AU2021200137B2 (en) * | 2013-07-17 | 2023-07-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
AU2014290568B2 (en) * | 2013-07-17 | 2020-10-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
US10174341B2 (en) | 2013-07-17 | 2019-01-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production |
WO2016037164A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
WO2016037162A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
US11279951B2 (en) | 2014-10-09 | 2022-03-22 | Genvec, Inc. | Adenoviral vector encoding human atonal homolog-1 (HATH1) |
US9951351B2 (en) | 2014-10-09 | 2018-04-24 | Genvec, Inc. | Adenoviral vector encoding human atonal homolog-1 (HATH1) |
EP4089166A1 (en) | 2016-01-27 | 2022-11-16 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
US10391132B2 (en) | 2016-01-27 | 2019-08-27 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
WO2017132552A1 (en) | 2016-01-27 | 2017-08-03 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
US11452750B2 (en) | 2016-01-27 | 2022-09-27 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
WO2017165813A1 (en) | 2016-03-25 | 2017-09-28 | Periphagen, Inc. | High-transducing hsv vectors |
EP3432912A4 (en) * | 2016-03-25 | 2019-09-18 | PeriphaGen, Inc. | High-transducing hsv vectors |
EP4212169A1 (en) * | 2016-03-25 | 2023-07-19 | PeriphaGen, Inc. | High-transducing hsv vectors |
US11753653B2 (en) | 2016-03-25 | 2023-09-12 | Periphagen, Inc. | High-transducing HSV vectors |
US10799560B2 (en) | 2016-03-25 | 2020-10-13 | Periphagen, Inc. | HSV vectors for delivery of NT3 and treatment of CIPN |
WO2018035141A1 (en) | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
WO2018039333A1 (en) | 2016-08-23 | 2018-03-01 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
US11365226B2 (en) | 2016-09-08 | 2022-06-21 | 2Seventy Bio, Inc. | PD-1 homing endonuclease variants, compositions, and methods of use |
EP4248979A2 (en) | 2016-09-08 | 2023-09-27 | 2seventy bio, Inc. | Pd-1 homing endonuclease variants, compositions, and methods of use |
WO2018049226A1 (en) | 2016-09-08 | 2018-03-15 | Bluebird Bio, Inc. | Pd-1 homing endonuclease variants, compositions, and methods of use |
US11912746B2 (en) | 2016-09-08 | 2024-02-27 | 2Seventy Bio, Inc. | PD-1 homing endonuclease variants, compositions, and methods of use |
US11530395B2 (en) | 2016-10-17 | 2022-12-20 | 2Seventy Bio, Inc. | TGFBetaR2 endonuclease variants, compositions, and methods of use |
EP4353822A2 (en) | 2016-11-17 | 2024-04-17 | 2seventy bio, Inc. | Tgf beta signal convertor |
WO2018094244A1 (en) | 2016-11-17 | 2018-05-24 | Bluebird Bio, Inc. | TGFβ SIGNAL CONVERTOR |
WO2018129268A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
EP4317447A2 (en) | 2017-02-15 | 2024-02-07 | 2seventy bio, Inc. | Donor repair templates multiplex genome editing |
WO2018152325A1 (en) | 2017-02-15 | 2018-08-23 | Bluebird Bio, Inc. | Donor repair templates multiplex genome editing |
WO2018176103A1 (en) | 2017-03-30 | 2018-10-04 | The University Of Queensland | "chimeric molecules and uses thereof" |
US11732255B2 (en) | 2017-05-25 | 2023-08-22 | 2Seventy Bio, Inc. | CBLB endonuclease variants, compositions, and methods of use |
US10927367B2 (en) | 2017-05-25 | 2021-02-23 | Bluebird Bio, Inc. | CBLB endonuclease variants, compositions, and methods of use |
US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
US11779654B2 (en) | 2017-10-04 | 2023-10-10 | 2Seventy Bio, Inc. | PCSK9 endonuclease variants, compositions, and methods of use |
WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2019165436A1 (en) | 2018-02-26 | 2019-08-29 | Antolrx | Tolerogenic liposomes and methods of use thereof |
WO2019241685A1 (en) | 2018-06-14 | 2019-12-19 | Bluebird Bio, Inc. | Cd79a chimeric antigen receptors |
US10793843B2 (en) | 2018-10-04 | 2020-10-06 | Bluebird Bio, Inc. | CBLB endonuclease variants, compositions, and methods of use |
WO2020185298A1 (en) * | 2019-03-14 | 2020-09-17 | Massachusetts Institute Of Technology | Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof |
WO2020223205A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
WO2020243261A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
WO2021072310A1 (en) | 2019-10-10 | 2021-04-15 | Oncorus, Inc. | Dual viruses and dual oncolytic viruses and methods of treatment |
WO2021207636A2 (en) | 2020-04-10 | 2021-10-14 | Sola Biosciences Llc | Compositions and methods for the treatment of protein aggregation disorders |
WO2021222168A2 (en) | 2020-04-28 | 2021-11-04 | Sola Biosciences Llc | Compositions and methods for the treatment of tdp-43 proteinopathies |
WO2021248038A1 (en) | 2020-06-05 | 2021-12-09 | Sola Biosciences Llc | Compositions and methods for the treatment of synucleinopathies |
WO2021252549A1 (en) | 2020-06-09 | 2021-12-16 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
WO2022093736A1 (en) | 2020-10-26 | 2022-05-05 | Sola Biosciences Llc | Compositions and methods for the treatment of alzheimer's disease |
WO2023288267A1 (en) | 2021-07-14 | 2023-01-19 | 2Seventy Bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
WO2023060221A2 (en) | 2021-10-08 | 2023-04-13 | Sola Biosciences Llc | Compositions and methods for the treatment of proteopathies |
WO2023060248A1 (en) | 2021-10-08 | 2023-04-13 | Sola Biosciences Llc | Compositions and methods for the treatment of p53-mediated cancers |
WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
Also Published As
Publication number | Publication date |
---|---|
US5804413A (en) | 1998-09-08 |
EP0904395B1 (en) | 2008-05-21 |
AU733945B2 (en) | 2001-05-31 |
AU3137997A (en) | 1998-05-05 |
EP0904395B2 (en) | 2011-07-27 |
JP2001503611A (en) | 2001-03-21 |
EP0904395A1 (en) | 1999-03-31 |
ATE396274T1 (en) | 2008-06-15 |
DE69738709D1 (en) | 2008-07-03 |
CA2255939A1 (en) | 1998-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0904395B2 (en) | Herpes simplex virus strains | |
US6261552B1 (en) | Herpes simplex virus vectors | |
US5879934A (en) | Herpes simplex virus strains for gene transfer | |
US5658724A (en) | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use | |
Krisky et al. | Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications | |
US6719982B1 (en) | Mutant herpes simplex viruses and uses thereof | |
McCarthy et al. | Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient | |
US5998174A (en) | Multigene vectors | |
US6248320B1 (en) | HSV strain lacking functional ICP27 and ICP34.5 genes | |
EP0840795A1 (en) | Helper virus-free herpesvirus vector packaging system | |
Zaupa et al. | Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes | |
Preston et al. | Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression | |
Rice et al. | Isolation and analysis of adenovirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein | |
KR20220016150A (en) | Recombinant Herpesvirales Vectors | |
Latchman | Herpes simplex virus vectors for gene therapy | |
Burton et al. | Replication-defective genomic herpes simplex vectors: design and production | |
US7262033B1 (en) | Cell lines for the propagation of mutated herpes viruses | |
Rinaldi et al. | A non-cytotoxic herpes simplex virus vector which expresses Cre recombinase directs efficient site specific recombination | |
Yamada et al. | Isolation and characterization of mutants of pseudorabies virus with deletion in the immediate-early regulatory gene | |
Burton et al. | Use of the herpes simplex viral genome to construct gene therapy vectors | |
MXPA01001192A (en) | Cell lines for the propagation of mutated herpes viruses | |
Johnson | HSV Recombinant Vectors: General Characteristics and Potential for Use in the Central Nervous System |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page |
Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997926668 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2255939 Country of ref document: CA Ref country code: CA Ref document number: 2255939 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09194274 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 512036 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997926668 Country of ref document: EP |